US EditionPublished • loading... • Updated
Vidac Pharma Presents a Case of “Compassionate Use” in Pediatric Brain Tumor at the Eilat Symposium on Pediatric Cancer
Summary by Mittelstand Cafe
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
London, UK, March 3, 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that it presented results from a compassionate use case involving its lead drug candidate VDA-1102 at the Eilat Symposium on Paediatric Cancer. The case involved a four-year-old girl diagnosed with recurrent ependymoma who was awaiting a third gestational age.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
